Celularity Inc (CELU)vsMerck & Company Inc (MRK)
CELU
Celularity Inc
$0.93
-2.68%
HEALTHCARE · Cap: $32.01M
MRK
Merck & Company Inc
$109.18
-1.60%
HEALTHCARE · Cap: $274.03B
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 160112% more annual revenue ($65.01B vs $40.58M). MRK leads profitability with a 28.1% profit margin vs -198.8%. MRK earns a higher WallStSmart Score of 59/100 (C).
CELU
Avoid19
out of 100
Grade: F
MRK
Buy59
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+86.7%
Fair Value
$9.22
Current Price
$0.93
$8.29 discount
Margin of Safety
-13.2%
Fair Value
$96.48
Current Price
$109.18
$12.70 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
No standout strengths identified
Mega-cap, among the largest globally
Every $100 of equity generates 37 in profit
Strong operational efficiency at 32.8%
Keeps 28 of every $100 in revenue as profit
Attractively priced relative to earnings
Generating 1.8B in free cash flow
Areas to Watch
Smaller company, higher risk/reward
ROE of -6367.0% — below average capital efficiency
Revenue declined 43.2%
Earnings declined 61.3%
Weak financial health signals
Expensive relative to growth rate
Earnings declined 19.3%
Comparative Analysis Report
WallStSmart ResearchBull Case : CELU
CELU has a balanced fundamental profile.
Bull Case : MRK
The strongest argument for MRK centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 28.1% and operating margin at 32.8%.
Bear Case : CELU
The primary concerns for CELU are Market Cap, Return on Equity, Revenue Growth.
Bear Case : MRK
The primary concerns for MRK are Piotroski F-Score, PEG Ratio, EPS Growth.
Key Dynamics to Monitor
CELU profiles as a turnaround stock while MRK is a value play — different risk/reward profiles.
CELU carries more volatility with a beta of 0.70 — expect wider price swings.
MRK is growing revenue faster at 5.0% — sustainability is the question.
MRK generates stronger free cash flow (1.8B), providing more financial flexibility.
Bottom Line
MRK scores higher overall (59/100 vs 19/100), backed by strong 28.1% margins. CELU offers better value entry with a 86.7% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Celularity Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Celularity Inc. is an innovative biotechnology company dedicated to pioneering regenerative medicine through its proprietary cellular products derived from the placenta. The firm boasts a robust pipeline of next-generation immunotherapies, including allogeneic off-the-shelf solutions, targeted at improving treatment efficacy and minimizing complications for cancer and other serious diseases. Supported by a seasoned leadership team and strategic collaborations, Celularity is strategically positioned to meet substantial unmet medical needs, thereby establishing itself as a pivotal entity in the dynamic landscape of advanced therapeutics.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?